Stem cell therapy represents one of the most promising and rapidly advancing therapeutic frontiers for neurodegenerative
/diseases—conditions characterized by the progressive and irreversible loss of specific [neuronal] populations. Unlike conventional
pharmacological approaches that aim to modulate symptoms or slow disease progression, stem cell-based strategies offer the theoretical potential to
replace lost neurons, restore disrupted neural circuits, and provide trophic support to surviving cells [1]
[2].
Over the past 15 years, more than 76 stem cell therapy trials have been conducted for Alzheimer's disease and Parkinson's disease alone, with more
than half occurring in the past five years, reflecting the accelerating pace of translational research in this field [1].
The field has been catalyzed by advances in induced pluripotent stem cell (iPSC) technology, which enables the generation of patient-specific or
donor-matched pluripotent cells from adult somatic cells, circumventing many of the ethical concerns associated with embryonic stem cells. Landmark
Phase I/II trials in Parkinson's Disease—including the Japanese iPSC-derived dopaminergic neuron trial published in Nature in 2025 [3]
and BlueRock Therapeutics' bemdaneprocel (hESC-derived) program advancing to Phase III [4]—mark
a turning point for cell therapy in neurodegeneration, with similar approaches to Alzheimer's Disease and amyotrophic lateral sclerosis (ALS) also
showing early signs of promise.
Embryonic stem cells are derived from the inner cell mass of blastocysts and possess unlimited self-renewal capacity and the ability to differentiate
into any cell type (pluripotency). Human ESCs (hESCs) have been used to generate high-purity populations of dopaminergic neurons, motor neurons,
and other neural cell types for transplantation studies [2].
The most advanced clinical programs using hESC-derived cells include:
Ethical concerns regarding embryo destruction and the requirement for immunosuppression in allogeneic transplantation remain important considerations
[6].
iPSCs are generated by reprogramming adult somatic cells (typically skin fibroblasts or blood cells) to a pluripotent state through expression of
defined transcription factors (Oct4, Sox2, Klf4, c-Myc). iPSC technology, pioneered by Shinya Yamanaka in 2006, enables the creation of
patient-specific pluripotent cells without embryo destruction [1].
Key advantages of iPSCs:
The Japanese iPSC-derived dopaminergic neuron trial, published in Nature in April 2025, demonstrated that allogeneic iPSC-derived dopaminergic
progenitors survived in the brains of patients with Parkinson's Disease, produced dopamine, and did not form tumors, establishing safety and
suggesting potential clinical benefit [3].
MSCs are multipotent stromal cells found in bone marrow, adipose tissue, umbilical cord blood, and other tissues. While MSCs have limited capacity to
differentiate into functional neurons, they exert neuroprotective effects primarily through paracrine mechanisms [2]:
Parkinson's Disease is the most advanced application of stem cell therapy in neurodegeneration, owing to the relatively focal nature of the primary
pathology—loss of dopaminergic neurons in the substantia nigra pars compacta. The concept of cell replacement for Parkinson's Disease was
validated in the 1980s–1990s by fetal ventral mesencephalic tissue transplantation studies, which demonstrated that transplanted dopamine neurons
could survive, reinnervate the striatum, and improve motor symptoms in some patients [7].
Current Clinical Trials:
| Trial | Cell Source | Phase | Status | Key Findings |
|---|---|---|---|---|
| Kyoto University (Japan) | iPSC-derived DA progenitors | I/II | Published (Nature, 2025) | Cells survived, produced dopamine, no tumors; 73 mild/moderate AEs [3] |
| Bemdaneprocel (BlueRock/Bayer) | hESC-derived DA progenitors | III (starting) | Active | Phase I: 21.9-point UPDRS-III improvement at high dose; advancing to ~102-patient Phase III [4] |
| STEM-PD (Lund/Cambridge) | hESC-derived DA neurons | I/II | Active | Advancing to higher dose cohorts [5] |
The bemdaneprocel Phase I trial (12 patients) showed particularly encouraging results: high-dose recipients demonstrated a mean 21.9-point reduction
in the Unified Parkinson's Disease Rating Scale (UPDRS) Part III motor score compared with baseline, with good tolerability and no serious
drug-related adverse events at 24 months post-surgery. The program is now advancing to a randomized, sham surgery-controlled Phase III trial with
approximately 102 patients [4].
Stem cell therapy for Alzheimer's Disease faces unique challenges because the pathology is diffuse, affecting multiple brain regions and cell types.
Unlike Parkinson's Disease, Alzheimer's does not involve the loss of a single defined neuronal population but rather a widespread degeneration driven
by amyloid-beta plaques, tau] tangles, neuroinflammation, and synaptic dysfunction [1].
Current approaches focus on:
Preclinical studies in transgenic Alzheimer's mouse models have shown that MSC transplantation can reduce amyloid plaque burden (potentially through
enhanced microglial phagocytosis), decrease neuroinflammatory markers, promote autophagy-mediated clearance, and improve cognitive performance in
behavioral assays [1].
ALS involves the progressive loss of upper and lower motor neurons, presenting both challenges and opportunities for cell therapy. Current stem cell
approaches for ALS include [2]:
Clinical trials include NurOwn (MSC-NTF cells, autologous MSCs engineered to secrete neurotrophic factors), which showed mixed results in Phase III.
Huntington's disease involves the progressive degeneration of GABAergic medium spiny neurons in the striatum. Fetal striatal tissue transplantation
was tested in clinical trials in the early 2000s with variable results. Current approaches focus on iPSC-derived GABAergic neurons and MSC-mediated
neuroprotection [2].
For multiple sclerosis, stem cell strategies focus on remyelination through transplantation of oligodendrocyte progenitor cells, as well as autologous hematopoietic stem cell transplantation (aHSCT) to "reset" the immune system. aHSCT has shown remarkable efficacy in aggressive relapsing-remitting MS, with some patients achieving long-term disease-free status.
A major challenge is ensuring that transplanted cells survive the hostile microenvironment of the diseased brain, integrate into existing circuits,
and form functional synaptic connections. Cell survival rates in early transplantation studies have often been low (5–20%), though optimized protocols
and co-transplantation with supportive factors have improved outcomes [7].
The pluripotent nature of ESCs and iPSCs raises concerns about teratoma formation from residual undifferentiated cells. Rigorous differentiation
protocols, cell sorting, and extended in vitro maturation are employed to minimize this risk. To date, no tumor formation has been reported in
clinical trials using highly purified neural progenitors [3].
Allogeneic stem cell transplants require immunosuppressive therapy to prevent graft rejection. Autologous iPSC-derived cells could theoretically
circumvent this requirement, but the lengthy and costly reprogramming and differentiation process for individual patients presents logistical
challenges. "Off-the-shelf" approaches using HLA-matched or HLA-engineered universal donor cells are being developed to balance immunocompatibility
with scalability [6].
Optimal delivery of stem cells to the central nervous system remains challenging:
Each neurodegenerative disease presents unique challenges for cell therapy:
Combining gene editing with stem cell technology offers new possibilities [9]:
Brain organoids—three-dimensional structures grown from stem cells that recapitulate aspects of brain architecture—are being explored both as research tools and potential therapeutic modalities. Organoid transplantation may provide more physiologically organized tissue grafts compared with dissociated cell suspensions.
An emerging approach uses the secreted factors (secretome) or extracellular vesicles ([exosomes) from stem cells rather than the cells themselves. This "cell-free" approach may retain many of the paracrine benefits of stem cell therapy while avoiding risks associated with cell transplantation.
As of 2025, the global clinical trial landscape for stem cell therapy in neurodegeneration includes [10]00445-4):
The study of Stem Cell Therapy For Neurodegenerative Diseases has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.